Lakefront Biotherapeutics | GLPG - Cash And Equivalent


Lakefront Biotherapeutics reported EUR66.8M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Incyte USD 4.02B 435.22M Mar/2026
Merck EUR 2.33B 77M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026